Rhenman & Partners Asset Management AB Sells 36,000 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Rhenman & Partners Asset Management AB lowered its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 24.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 114,000 shares of the company's stock after selling 36,000 shares during the quarter. Rhenman & Partners Asset Management AB owned about 0.39% of Dianthus Therapeutics worth $2,485,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp raised its position in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company's stock valued at $22,483,000 after buying an additional 413,425 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Dianthus Therapeutics by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 949,334 shares of the company's stock valued at $25,936,000 after purchasing an additional 273,670 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Dianthus Therapeutics by 151.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company's stock valued at $11,984,000 after purchasing an additional 263,500 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock worth $25,283,000 after purchasing an additional 136,633 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock worth $4,543,000 after purchasing an additional 97,362 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Trading Down 8.1 %

Shares of DNTH traded down $1.33 during midday trading on Thursday, hitting $15.00. The stock had a trading volume of 340,441 shares, compared to its average volume of 256,258. The business has a 50-day simple moving average of $20.89 and a two-hundred day simple moving average of $23.53. The firm has a market cap of $481.88 million, a P/E ratio of -6.00 and a beta of 1.62. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating on the stock. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Finally, Guggenheim restated a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.